Pay in 4 interest-free payments of $6.80 Learn more
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24
Firoze Khan [email protected] This article was submitted to Autoimmune and Autoinflammatory Disorders, a section of the journal Frontiers in Immunology Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers
GLP-1 receptor agonists are licensed to treat diabetes and obesity, but data on whether these medications alleviate or exacerbate anxiety, depression, and self-harm are mixed
The first versions of GLP-1s were injectable drugs that people had to give themselves weekly
Al-Kuraishy HM
Like most chronic therapies, GLP-1s are most effective when used consistently, so a formulation that encourages long-term use could have a meaningful impact on patient outcomes.
However, a direct comparison of the BP-lowering effects of these two types of antidiabetic drugs has not been reported
